The trial evaluates the efficacy of Liraglutide versus Exenatide in combination with existing oral anti-diabetic treatments for Type 2 diabetes. Given the growing prevalence of diabetes globally, the market for GLP-1 receptor agonists is expanding, with significant competition from other diabetes therapies. The results could reinforce Novo Nordisk's position in the diabetes market, particularly if Liraglutide demonstrates superior efficacy or safety compared to Exenatide. Diligence should focus on the competitive landscape, including pricing strategies and market access considerations, as well as potential regulatory hurdles for new indications.